Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Clearpoint Neuro Inc(CLPT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CLPT
09/25/2026: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.
Clearpoint Neuro is a specialized medical technology company that provides an MRI-guided navigation platform for complex brain procedures. The company has a notable position in the emerging field of neuro-interventional drug delivery, which serves as its primary growth opportunity. Its main strengths include its unique technological platform and strategic partnerships with major biotech firms. However, it faces significant risks including competition from large-cap MedTech incumbents, reliance on third-party clinical trial success, and a history of operating losses. This stock is generally better suited for growth-oriented investors with a high risk tolerance who are looking for exposure to the long-term evolution of neuro-therapeutics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in the high-growth neuro-interventional and gene therapy space with a scalable platform. |
| Momentum investor | Mixed fit | This is a volatile small-cap that requires positive market signal to support momentum strategies. |
| Value investor | Weak fit | The company is not currently focused on profitability or traditional value metrics. |
| Dividend investor | Weak fit | No dividend is paid, as all cash is reinvested into growth. |
| Low-risk investor | Weak fit | The company's small-cap status and ongoing losses present significant risk to capital. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a small-cap growth stock, share prices can experience sharp swings based on news flow. |
| Valuation risk | Medium / high | High expectations for future growth are already priced into the stock, leaving little margin for error. |
| Competition risk (MedTech giants) | High | Large incumbents like Medtronic have massive distribution power that can overwhelm niche players. |
| Business quality | Medium | The company has strong technological differentiation but is still scaling toward consistent profitability. |
| Dividend income | Low / none | The stock provides no income to investors. |
| Execution risk | Medium / high | Future success depends on the company's ability to maintain partnerships and support complex clinical trials. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -17.43% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 445.67M USD | Price to earnings Ratio - | 1Y Target Price 23.5 |
Price to earnings Ratio - | 1Y Target Price 23.5 | ||
Volume (30-day avg) 554.3K shares | Beta 1.27 | 52 Weeks Range 8.27 - 30.10 | Updated Date 09/24/2026 |
52 Weeks Range 8.27 - 30.10 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Navigation and Access | ClearPoint System hardware and software, disposables, and procedural kits. | The foundational revenue stream from neurosurgeons using the system. |
| Biologics and Drug Delivery | Clinical trial support, SmartFlow cannula sales, and collaborative research services. | The long-term growth engine tied to new brain therapies. |
| Geography | Primarily US-based revenues with emerging efforts in European markets. | Success is currently concentrated in the US market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 12.11 | Enterprise Value 491.84M | Price to Sales(TTM) 10.54 |
Enterprise Value 491.84M | Price to Sales(TTM) 10.54 | ||
Enterprise Value to Revenue 11.63 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 30.50M | Shares Floating 26.28M |
Shares Outstanding 30.50M | Shares Floating 26.28M | ||
Percent Insiders 5.48 | Percent Institutions 52.47 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Clearpoint Neuro Inc
Exchange NASDAQ | Headquarters Solana Beach, CA, United States | ||
IPO Launch date 2020-02-12 | President, CEO & Director Mr. Joseph Michael Burnett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 160 | Website https://www.clearpointneuro.com |
Full time employees 160 | Website https://www.clearpointneuro.com | ||
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.